Hepion Pharmaceuticals, Inc. (HEPA)
0.14
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Hepion Pharmaceuticals Net Income (Quarterly) : -1.248M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.248M |
| March 31, 2026 | -0.8108M |
| December 31, 2025 | -0.6569M |
| September 30, 2025 | -0.4725M |
| June 30, 2025 | -1.043M |
| March 31, 2025 | -6.106M |
| December 31, 2024 | -1.548M |
| September 30, 2024 | -4.866M |
| June 30, 2024 | -3.925M |
| March 31, 2024 | -2.854M |
| December 31, 2023 | -11.06M |
| September 30, 2023 | -10.53M |
| June 30, 2023 | -14.08M |
| March 31, 2023 | -13.26M |
| December 31, 2022 | -6.812M |
| September 30, 2022 | -8.548M |
| June 30, 2022 | -19.91M |
| March 31, 2022 | -6.930M |
| December 31, 2021 | -9.733M |
| September 30, 2021 | -9.270M |
| June 30, 2021 | -7.667M |
| March 31, 2021 | -6.064M |
| December 31, 2020 | -4.956M |
| September 30, 2020 | -6.232M |
| Date | Value |
|---|---|
| June 30, 2020 | -4.940M |
| March 31, 2020 | -4.227M |
| December 31, 2019 | -1.894M |
| September 30, 2019 | -1.820M |
| June 30, 2019 | -1.021M |
| March 31, 2019 | -1.984M |
| December 31, 2018 | -2.573M |
| September 30, 2018 | -0.1571M |
| June 30, 2018 | -4.029M |
| March 31, 2018 | -2.690M |
| September 30, 2017 | -5.774M |
| March 31, 2017 | -5.774M |
| June 30, 2016 | -5.206M |
| March 31, 2016 | -3.918M |
| December 31, 2015 | -3.030M |
| September 30, 2015 | -4.844M |
| June 30, 2015 | -5.375M |
| March 31, 2015 | -4.398M |
| December 31, 2014 | -3.104M |
| September 30, 2014 | -1.470M |
| June 30, 2014 | 4.381M |
| March 31, 2014 | -9.312M |
| December 31, 2013 | -0.1682M |
| September 30, 2013 | -0.1821M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.248M |
| EPS Diluted (Quarterly) | -0.0771 |
| Enterprise Value | 4.143M |
| Earnings Yield | -174.4% |
| Normalized Earnings Yield | -173.07 |